Published in Lancet on April 08, 1989
Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev (1998) 9.76
Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype. J Clin Microbiol (1994) 3.64
Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol (1994) 3.51
Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole. J Clin Microbiol (1993) 2.06
In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob Agents Chemother (1994) 1.95
Fluconazole- and itraconazole-resistant Candida albicans strains from AIDS patients: multilocus enzyme electrophoresis analysis and antifungal susceptibilities. J Clin Microbiol (1995) 1.44
Typing Candida albicans oral isolates from human immunodeficiency virus-infected patients by multilocus enzyme electrophoresis and DNA fingerprinting. J Clin Microbiol (1996) 1.32
Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother (1990) 1.07
Practical advice for the gastroenterologist dealing with symptomatic HIV disease. Gut (1990) 1.05
Uptake and intracellular activity of fluconazole in human polymorphonuclear leukocytes. Antimicrob Agents Chemother (1993) 0.97
Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection. HIV AIDS (Auckl) (2010) 0.92
Large-scale multicentre study of fluconazole in the treatment of hospitalised patients with fungal infections. Multicentre European Study Group. Eur J Clin Microbiol Infect Dis (1997) 0.91
Influence of local radiotherapy on penetration of fluconazole into human saliva. Antimicrob Agents Chemother (1993) 0.91
Antimicrobial therapy for the treatment of opportunistic infections in HIV/AIDS patients: a critical appraisal. HIV AIDS (Auckl) (2011) 0.87
Role of posaconazole in the management of oropharyngeal and esophageal candidiasis. Ther Clin Risk Manag (2007) 0.85
Multicenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumonia. PLoS One (2014) 0.81
Fluconazole in the treatment of candidiasis in immunocompromised children. Antimicrob Agents Chemother (1991) 0.81
Evaluating diagnosis and treatment of oral and esophageal candidiasis in Ugandan AIDS patients. Emerg Infect Dis (1999) 0.80
Fluconazole (Diflucan). Infect Dis Obstet Gynecol (1995) 0.76
Safety and efficacy of fluconazole treatment for Candida oesophagitis in AIDS. Postgrad Med J (1991) 0.75
Pharmacokinetics of two multiple-dosing regimens of D0870 in human immunodeficiency virus-positive patients: a phase I study. Antimicrob Agents Chemother (1998) 0.75
Fluconazole versus ketoconazole in oropharyngeal candidiasis in AIDS. Lancet (1989) 0.75
Proceedings of the British Pharmacological Society. 12-14 September 1990, Belfast. Br J Clin Pharmacol (1991) 0.75
CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med (2006) 22.76
Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections. J Infect Dis (1974) 5.47
Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group. N Engl J Med (1993) 4.88
Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis (2000) 4.24
Variation in antibiotic prescribing and its impact on recovery in patients with acute cough in primary care: prospective study in 13 countries. BMJ (2009) 3.95
A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med (1995) 3.89
Use of specialised isolation media for recognition and identification of Candida dubliniensis isolates from HIV-infected patients. Eur J Clin Microbiol Infect Dis (1997) 3.86
Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect (2004) 3.71
Hospital consumption of antibiotics in 15 European countries: results of the ESAC Retrospective Data Collection (1997-2002). J Antimicrob Chemother (2006) 3.09
Female prostitutes: a risk group for infection with human T-cell lymphotropic virus type III. Lancet (1985) 2.84
Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med (1993) 2.78
Isolation of AIDS virus from cell-free breast milk of three healthy virus carriers. Lancet (1985) 2.77
Preparedness for admission of patients with suspected Ebola virus disease in European hospitals: a survey, August-September 2014. Euro Surveill (2014) 2.65
Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med (1992) 2.57
Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. AIDS in Europe Study Group. JAMA (1994) 2.56
Discrimination among thermophilic Campylobacter species by polymerase chain reaction amplification of 23S rRNA gene fragments. J Clin Microbiol (1993) 2.54
Detection of Mycoplasma pneumoniae by two polymerase chain reactions and role of M. pneumoniae in acute respiratory tract infections in pediatric patients. J Infect Dis (1996) 2.51
Comparative evaluation of NASBA HIV-1 RNA QT, AMPLICOR-HIV monitor, and QUANTIPLEX HIV RNA assay, three methods for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (1996) 2.45
Rapid and economical method for species identification of clinically significant coagulase-negative staphylococci. J Clin Microbiol (1995) 2.43
Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU28965 (a new macrolide), and other agents against enteropathogens. Antimicrob Agents Chemother (1985) 2.36
The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial use. Euro Surveill (2012) 2.29
Modified selective medium for isolation of Campylobacter spp. from feces: comparison with Preston medium, a blood-free medium, and a filtration system. J Clin Microbiol (1986) 2.25
Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups. JAMA (1999) 2.16
Antibiotic prescribing for adults with acute cough/lower respiratory tract infection: congruence with guidelines. Eur Respir J (2011) 2.13
Relevance of nucleic acid amplification techniques for diagnosis of respiratory tract infections in the clinical laboratory. Clin Microbiol Rev (1997) 2.11
Presence of vancomycin-resistant enterococci in farm and pet animals. Antimicrob Agents Chemother (1996) 2.06
Acquired immunodeficiency syndrome in Rwanda. Lancet (1984) 2.05
Campylobacter upsaliensis enteritis associated with canine infections. Lancet (1991) 2.05
Vancomycin-resistant enterococci colonizing the intestinal tracts of hospitalized patients. J Clin Microbiol (1995) 2.04
A new selective medium for the isolation of Campylobacter jejuni from human faeces. Eur J Clin Microbiol (1983) 2.03
Differentiated Caco-2 cells as a model for enteric invasion by Campylobacter jejuni and C. coli. J Med Microbiol (1992) 1.91
Cephradine. Antibacterial activity and clinical effectiveness. Chemotherapy (1973) 1.88
Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes and Streptococcus pneumoniae isolates. J Antimicrob Chemother (2000) 1.87
Human immunodeficiency virus transmission among heterosexual couples in Central Africa. AIDS (1988) 1.87
Chemotaxonomic analyses of Bacteroides gracilis and Bacteroides ureolyticus and reclassification of B. gracilis as Campylobacter gracilis comb. nov. Int J Syst Bacteriol (1995) 1.81
Evaluation of NucliSens easyMAG for automated nucleic acid extraction from various clinical specimens. J Clin Microbiol (2006) 1.73
Acquired immunodeficiency syndrome in African patients. N Engl J Med (1984) 1.70
Development of species-specific DNA probes for Campylobacter jejuni, Campylobacter coli, and Campylobacter lari by polymerase chain reaction fingerprinting. J Clin Microbiol (1993) 1.67
Antimicrobial susceptibilities of Campylobacter strains isolated from food animals in Belgium. J Antimicrob Chemother (2001) 1.62
Molecular diagnosis of Mycoplasma pneumoniae respiratory tract infections. J Clin Microbiol (2003) 1.61
Antibody to HTLV-III in blood donors in central Africa. Lancet (1985) 1.61
Survey of enterococcal susceptibility patterns in Belgium. J Clin Microbiol (1996) 1.58
Performance of the recommendations of a British advisory group for screening for chlamydia in a sample of women in general practice. J Med Screen (2003) 1.56
European surveillance of antimicrobial consumption (ESAC): data collection performance and methodological approach. Br J Clin Pharmacol (2004) 1.54
Comparison of screening methods for detection of extended-spectrum beta-lactamases and their prevalence among blood isolates of Escherichia coli and Klebsiella spp. in a Belgian teaching hospital. J Clin Microbiol (1997) 1.54
Avoparcin and virginiamycin as animal growth promoters: a plea for science in decision-making. Clin Microbiol Infect (2000) 1.54
Susceptibility pattern of Campylobacter jejuni from human and animal origins to different antimicrobial agents. Antimicrob Agents Chemother (1982) 1.52
Evaluation of arbitrarily primed PCR analysis and pulsed-field gel electrophoresis of large genomic DNA fragments for identification of enterococci important in human medicine. Int J Syst Bacteriol (1997) 1.50
Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother (2007) 1.47
Dissemination of an NDM-2-producing Acinetobacter baumannii clone in an Israeli rehabilitation center. Antimicrob Agents Chemother (2011) 1.43
Survival differences in European patients with AIDS, 1979-89. The AIDS in Europe Study Group. BMJ (1994) 1.41
Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia. Antimicrob Agents Chemother (1984) 1.41
Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis (1996) 1.40
Evaluation of the discriminatory power of typing methods for Neisseria gonorrhoeae. J Clin Microbiol (1999) 1.39
Antibiotic prescribing for discoloured sputum in acute cough/lower respiratory tract infection. Eur Respir J (2011) 1.39
Acquired immune deficiency syndrome in Black Africans. Lancet (1983) 1.38
Comparison of direct plating and broth enrichment culture for the detection of intestinal colonization by glycopeptide-resistant enterococci among hospitalized patients. J Clin Microbiol (1999) 1.37
Optimal sampling sites and methods for detection of pathogens possibly causing community-acquired lower respiratory tract infections. J Clin Microbiol (2008) 1.36
Healthcare-associated infections: think globally, act locally. Clin Microbiol Infect (2008) 1.35
A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr (1999) 1.35
A prospective study of the ophthalmologic findings in the acquired immune deficiency syndrome in Africa. Am J Ophthalmol (1985) 1.33
Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). Clin Infect Dis (1994) 1.32
Seroepidemiological studies of HTLV-III antibody prevalence among selected groups of heterosexual Africans. JAMA (1985) 1.30
Specific detection of Campylobacter concisus by PCR amplification of 23S rDNA areas. Mol Cell Probes (1995) 1.29
Causes of death in febrile granulocytopenic cancer patients receiving empiric antibiotic therapy. Eur J Cancer Clin Oncol (1984) 1.28
Campylobacter pyloridis in children. Lancet (1986) 1.28
Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther (2004) 1.28
Performance of different mono- and multiplex nucleic acid amplification tests on a multipathogen external quality assessment panel. J Clin Microbiol (2011) 1.27
Semisolid selective-motility enrichment medium for isolation of salmonellae from fecal specimens. J Clin Microbiol (1984) 1.23
Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis (2012) 1.23
Taxonomy of Campylobacter, Arcobacter, and Helicobacter: a review. Zentralbl Bakteriol (1992) 1.21
Comparison of glycopeptide-resistant Enterococcus faecium isolates and glycopeptide resistance genes of human and animal origins. Antimicrob Agents Chemother (1999) 1.21
TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. HIV Med (2003) 1.20
Identification of clinically relevant viridans streptococci by analysis of transfer DNA intergenic spacer length polymorphism. Int J Syst Bacteriol (1999) 1.20
Typing of Mycoplasma pneumoniae by PCR-mediated DNA fingerprinting. J Clin Microbiol (1994) 1.19
Surveillance of antimicrobial resistance--what, how and whither? Clin Microbiol Infect (2001) 1.19
European Antibiotic Awareness Day: a five-year perspective of Europe-wide actions to promote prudent use of antibiotics. Euro Surveill (2014) 1.18
Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Med (2007) 1.17
European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe, 1998-2005. Euro Surveill (2007) 1.16
Effect of fluconazole on indinavir pharmacokinetics in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (1998) 1.15
Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 1.14
High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients. Clin Microbiol Infect (2006) 1.13
Detection of rhinoviruses by tissue culture and two independent amplification techniques, nucleic acid sequence-based amplification and reverse transcription-PCR, in children with acute respiratory infections during a winter season. J Clin Microbiol (2006) 1.13
Prevalence and mechanism of resistance against macrolides and lincosamides in Streptococcus suis isolates. Vet Microbiol (2001) 1.11
New selective medium for isolation of Campylobacter jejuni from faecal specimens. Lancet (1983) 1.08
Differential effect of human immunodeficiency virus infection on the IgA and IgG antibody responses to pneumococcal vaccine. J Infect Dis (1995) 1.08
The rapid evolution of HIV therapy. HIV Med (2000) 1.07
Acute respiratory infection due to Mycoplasma pneumoniae: current status of diagnostic methods. Eur J Clin Microbiol Infect Dis (2010) 1.07
Detection of Mycoplasma pneumoniae in spiked clinical samples by nucleic acid sequence-based amplification. J Clin Microbiol (2002) 1.06
Isolation of Candida species on media with and without added fluconazole reveals high variability in relative growth susceptibility phenotypes. Antimicrob Agents Chemother (1997) 1.06
Indicator disease-guided testing for HIV--the next step for Europe? HIV Med (2008) 1.05
European Antibiotic Awareness Day, 2008 - the first Europe-wide public information campaign on prudent antibiotic use: methods and survey of activities in participating countries. Euro Surveill (2009) 1.05
Polymerase chain reaction-mediated DNA fingerprinting for epidemiological studies on Campylobacter spp. J Med Microbiol (1994) 1.05
Use of ceftazidime in the therapy of serious infections, including those due to multiresistant organisms. Antimicrob Agents Chemother (1983) 1.04
Effect of antimicrobial therapy on the specific serological response to Helicobacter pylori infection. Eur J Clin Microbiol Infect Dis (1992) 1.03